Answers are grounded in this paper and cite their sources.
The authors defend the inclusion of CT-derived left atrial volume in the ATLAS score, noting it accounts for two-thirds of the score's prognostic power for predicting AF recurrence after ablation.
We would like to thank Prof. Mujović et al. for their interest in our manuscript Development and validation of a risk score for predicting atrial fibrillation recurrence after a first catheter ablation procedure: ATLAS score.1 The authors raise some interesting points in their letter,2 that we would like to address. First, we acknowledge that the inclusion of left atrial (LA) volume assessed by cardiac computed tomography (CT) is a limitation, in the sense that it requires imaging data that are not usually available when the decision to undergo atrial fibrillation (AF) ablation is being considered. However, we found a very strong association between LA volume and the outcome of AF ablation, suggesting that this variable may be essential for accurately assessing individual prognosis in this setting (LA volume alone accounts for two-thirds of the prognostic power of the score). Surely, further studies will be required to ascertain whether LA volume can be replaced by a more easily obtainable measure of LA dilatation, but the correlation between CT-derived LA volume and echocardiographic LA measurements is relatively poor (with the possible exception of three-dimensional assessment of LA volume).3 In fact, subgroup analysis in our cohort failed to show LA diameter as a predictor of AF relapse. Moreover, although CT and magnetic resonance imaging (MRI) aren’t readily available in some areas, one can easily predict that their availability and relevance will continue to grow (e.g. LA fibrosis assessed by MRI). Ultimately, the success of any score will depend on a balance between accuracy and ease of use. Second, it was not our intent to provide a comprehensive review of all the previously reported scores predicting the outcome of AF ablation, most of which were derived from small cohorts and/or did not undergo validation. Nevertheless, we believe that a prospective multicentre comparison between the properly derived and validated scores would be of great interest. Finally, we agree with Dr Mujović et al. that no score can replace a comprehensive clinical evaluation. We stand by our assertion that even though the ATLAS score was devised to estimate the rate of AF relapse and aid decision-making, it is no substitute for sound clinical judgement. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Mesquita et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: